# OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma

> **NCT07739017** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Olivia Newton-John Cancer Research Institute** · enrollment: 54 (estimated)

## Conditions studied

- Recurrent Glioblastoma
- Newly Diagnosed MGMT Unmethylated Glioblastoma

## Interventions

- **DRUG:** CT-179

## Key facts

- **NCT ID:** NCT07739017
- **Lead sponsor:** Olivia Newton-John Cancer Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2028-06
- **Final completion:** 2028-09
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739017, "OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*